Australia ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

Australia Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

Australia Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $355 Mn in 2022 and is projected to reach $707 Mn in 2030, exhibiting a CAGR of 9% during the forecast period. A total of $105.8 Bn, or 16.8% of total government expenditures in Australia, is projected to be spent on health in 2022–2023. In 2022–2023, the Australian Government's Pharmaceutical Benefits Scheme (PBS) medicine payments will account for the majority of the $17.2 Bn, or 16.3%, in pharmaceutical benefits and services. To support the proposals of the Strengthening Medicare Taskforce, which are due by the end of this year, the government has set aside $750 Mn for its Strengthening Medicare Fund.

Attention deficit hyperactivity disorder is a developmental disorder that starts in childhood. Children with ADHD may struggle to focus and become hyperactive, to the point where the condition interferes with their schoolwork, friendships, or family life. One in twenty Australians suffers from ADHD. Boys are more likely to have it. More than 3 out of 4 kids who are diagnosed with ADHD still exhibit the symptoms as adults. Executive functioning, or the capacity to self-regulate and control ideas, words, actions, and emotions, is impacted by ADHD.

Depending on the particular requirements of each child and family, there are multiple options for treating ADHD. Utilizing effective parenting techniques is frequently the first move. Maintaining a routine, assisting the kid in developing social skills, and working with the school to create a learning environment can all be beneficial. A combination of treatments including medication, psychotherapy, education, and knowledge treatments for adults can include medication, psychotherapy, education, or training in Australia. Both short-acting and long-acting medicines are available in Australia in a variety of forms. The most popular and well-known ADHD treatments are stimulants. When taking these quick-acting drugs, between 70 and 80 % of kids with ADHD experience reduced ADHD symptoms. In 2003, non-stimulants were authorized for the therapy of ADHD. Although they don't work as rapidly as stimulants, they can still have an impact for up to 24 hours. The most frequently recommended medications for ADHD are the stimulants methylphenidate and dexamphetamine in Australia. For some individuals, second-line treatments like tricyclic antidepressants, clonidine, moclobemide, and thioridazine have been used alone or in conjunction with a stimulant. The effectiveness of the other drugs has not yet been determined, despite the tricyclics having a comparable efficacy to that of the stimulants.

Market Dynamics

Market Growth Drivers

Due to an increase in the number of diagnosed cases, there has been a steady rise in the demand for ADHD medications in Australia. In response to this, the Australia ADHD therapeutics market has expanded as pharmaceutical firms have introduced new medications to meet the rising demand. The treatment choices for ADHD have significantly improved, primarily due to the development of long-acting drugs and non-pharmacological therapies. Because patients and healthcare professionals now have more choices for treating the disorder, this has helped the Australia ADHD therapeutics market to expand.

Market Restraints

The reasons most likely to impede the growth of the Australia attention-deficit hyperactivity disorder (ADHD) market in the upcoming years are the strict administration and governing procedures, the rise in drug prices, and the insufficient availability of non-stimulants medicines for ADHD. The quality of life of patients is also being restricted by the contraindications and side effects associated with ADHD medications, which is predicted to further hinder the expansion of the Australia ADHD therapeutics market in the near future.

Competitive Landscape

Key Players

• Tripak Pharmaceuticals (AUS)
• AcuraBio (AUS)
• Kira Biotech (AUS)
• Zucero Therapeutics (AUS)
• Atherton Pharmaceuticals (AUS)
• Novartis
• Noven Pharmaceuticals
• Shire
• Teva Pharmaceutical
• Impax Laboratories

Healthcare Policies and Regulatory Landscape

A drug must be approved by the Therapeutic Goods Administration (TGA) before it can be sold in Australia. Following the 1991 Baume report, the TGA's duties were rearranged. The TGA must assess the drugs' effectiveness, safety, and quality as well as their timely availability. Referrals to the Australian Drug Evaluation Committee (ADEC) are made for new chemical substances and applications that call for professional counsel. The TGA ultimately decides whether to register a drug for use in Australia, despite the ADEC's ability to make suggestions in this regard. The TGA is in charge of examining non-prescription medications, over-the-counter drugs, alternative medicines, and medical equipment in addition to prescription drugs. Drug regulation is a labor- and resource-intensive procedure. Regarding the quality, security, and effectiveness of medications made accessible in Australia, it must be held accountable. The acceptance of a balance between safety and effectiveness is a part of this responsibility.

Recently the Pharmaceutical Benefits Scheme (PBS) removed the age restriction (previously 18 years) to enable people over the age of 18 to be eligible to have a PBS Script for the treatment of ADHD.